2020
Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).
Lanzoni G, Linetsky E, Correa D, Alvarez R, Marttos A, Hirani K, Cayetano S, Castro J, Paidas M, Efantis Potter J, Xu X, Glassberg M, Tan J, Patel A, Goldstein B, Kenyon N, Baidal D, Alejandro R, Vianna R, Ruiz P, Caplan A, Ricordi C. Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS). CellR4-- Repair, Replacement, Regeneration, & Reprogramming 2020, 8 PMID: 34164564, PMCID: PMC8218794, DOI: 10.32113/cellr4_20204_2839.Peer-Reviewed Original ResearchAcute respiratory distress syndromeIntensive care unitCOVID-19 patientsAcute lung injurySerious adverse eventsRespiratory distress syndromeDiabetes Research InstituteJackson Memorial HospitalClinical trialsUC-MSCsAdverse eventsMesenchymal stem cellsUmbilical cordCytokine stormDistress syndromeCare unitALI/acute respiratory distress syndromeICU COVID-19 patientsEarly phase clinical trialsSevere COVID-19Uncontrolled clinical trialsImmune-based diseasesRegulatory cell populationsT cell reactionsInfusion of vehicle
2012
Inherited and Acquired Thrombophilias
Paidas M. Inherited and Acquired Thrombophilias. 2012, 108-120. DOI: 10.1002/9781119963783.ch15.Peer-Reviewed Original ResearchAntiphospholipid antibody syndromePlacenta-mediated complicationsAntibody syndromeThrombophilic conditionsProthrombin G20210A gene mutationFactor V Leiden mutationBenefits of anticoagulationCornerstone of treatmentProspective cohort studyRecurrent pregnancy lossAdequate clinical trialsV Leiden mutationAcquired ThrombophiliaAntiplatelet therapyCohort studyPregnancy lossThrombophilic mutationsClinical trialsLeiden mutationNatural anticoagulantsRoutine useThrombophiliaGene mutationsAnticoagulationComplications